Skip to content

Homeopathic treatment of sore throat in children

A double-blind, randomized, placebo-controlled trial of individualized homoeopathic medicines in improving the symptoms of acute viral tonsillitis in children

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/03/050305
Enrollment
78
Registered
2023-03-03
Start date
Unknown
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J038- Acute tonsillitis due to other specified organisms

Interventions

Intervention1: Individualized homoeopathic medicines in centesimal potencies plus concomitant care: Intervention is planned as administering the indicated homoeopathic medicines in centesimal potencie
doses and repetition depending upon the individual requirement of the cases. Patients will be advised to restrain from handling the globules or from eating, drinking, smoking or brushing teeth within
doses and repetition will be maintained depending upon the individual requirement of the cases. All sundry items will be procured from a Good Manufacturing Practice (GMP) certified firm. All the patie

Sponsors

D N De Homoeopathic Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Children suffering from acute sore throat of resent onset (= 5 on tonsillopharyngitis assessment (TPA) and viral aetiology confirmed by RTPCR, and bacterial origin will be excluded by bacterial culture. 2.Participants of either sex. 3.Age between 5 and 15 years. 4.Literate patientâ??s parents; ability to read and write in Bengali and/or English. Illiterate participants will be interviewed by the investigators maintaining adequate privacy to fill up the scale or questionnaires. 5.The parents providing written informed consent voluntarily and the children providing with informed assent.

Exclusion criteria

Exclusion criteria: 1.Causes other than viral. 2.Presence of uncontrolled co-morbidities. 3.Self-reported immune-compromised state. 4.Vulnerable population - unconscious, non-ambulatory, too sick for consultation, differently abled, terminally ill or critically ill patients, mentally incompetent people. 5.Simultaneous participation in any other clinical trials. 6.Exclusion of patient with COVID-19 as detected by the rapid antigen detection test.

Design outcomes

Primary

MeasureTime frame
Tonsillo-pharyngitis assessment (TPA) scoreTimepoint: Baseline, every day, up to 7 days, and 10th and 15th days.

Secondary

MeasureTime frame
Days to complete recoveryTimepoint: Baseline, every day, up to 7 days, and 10th and 15th days.;Days to remission of sore throatTimepoint: Baseline, every day, up to 7 days, and 10th and 15th days.;Sore throat pain model (STPM)Timepoint: Baseline, every day, up to 7 days, and 10th and 15th days.

Countries

India

Contacts

Public ContactShubhamoy Ghosh

D N De Homoeopathic Medical College and Hospital

shubhamoy67@gmail.com9831034229

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026